Prime Therapeutics to present findings at AMCP Conference in April
ST. PAUL, Minn., April 21 /PRNewswire/ -- Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, today announced the results of its study, "Association Between Tumor Necrosis Factor (TNF) Blocker Out-of-Pocket (OOP) Expense and Member Decline to Fill Rate". The study assessed the association between decline-to-fill rates as they relate to out-of-pocket expense for members initiating TNF-blocker therapy for the treatment of inflammatory conditions such as rheumatoid arthritis. The use of TNF blocker agents to treat rheumatoid arthritis has been increasing among the aging U.S. population and treatment for the disease is becoming more and more costly.(1)
Because of Prime's close working relationship with many large health plans, Prime is uniquely positioned to analyze both pharmaceutical and medical data to closely monitor drug safety, effectiveness, costs and prescribing practices. Through the evaluation of pharmacy claims of 4.4 million members from four major Blue Cross and Blue Shield Plans between July 2006 and June 2007, Prime was able to determine that members with an out-of-pocket cost greater than $250 were 4.6 times more likely to decline to fill their initial TNF-blocker medication.
In determining this, Prime found that more than six of seven members initiating TNF-blocker therapy had a per-claim, out-of-pocket expense of $100 or less with a low decline to fill rate of one in 50. The study also found that this decline to fill rate increased to at least one out of every 10 members when the out-of-pocket expense was $251 to $500 and grew to one out of every 5 when members paid the entire cost of greater than $1000. Members generally need to pay approximately $250 when they have a 20% coinsurance pharmacy benefit and they would have to pay the entire cost early in the year when their pharmacy benefit is a consumer directed healthcare product.
"From our findings, we believe that members who have an out of pocket expense of less than $100 per prescription fill are more likely to initiate treatment," said Patrick Gleason, PharmD, Director of Clinical Outcomes Assessment at Prime. "We also believe that the $250 out-of-pocket rate is an important value, and one that insurers should give consideration to, as it represents the expected out-of-pocket cost for members with a 20 percent co-insurance benefit."
Prime Therapeutics will be presenting this study at the 20th Annual
American Managed Care Pharmacy (AMCP) Conference on April 18 in San
Francisco. Other Prime poster presentations include:
-- Pioglitazone (Actos(R)) and Rosiglitazone (Avandia(R)) 2007
Utilization Trends and Prevalence of Cardiovascular Risk among
-- Pharmacy Management Heartburn: Lack of Medical Correlation with Proton
Pump Inhibitor Utilization
-- Assessment of Modafinil (Provigil(R)) Utilization Management
Opportunity: Integrated Medical and Pharmacy Claims Analysis
-- Statin Step-Therapy Program: Impact on Utilization and Cost
-- Assessment of an Insurer Letter to Providers Requesting They Initiate
Statin Therapy for Members at Major Adverse Cardiovascular Event Risk
1. Scott, D.L., Kingsley, G.H. Tumor necrosis factor inhibitors for
rheumatoid arthritis. NEJM 2006;355:704-12. Prime Therapeutics 2006
Drug Trend Insights
Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.6 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 10 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at http://www.primetherapeutics.com.
|SOURCE Prime Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved